Company research
OCULAR THERAPEUTIX, INC
CIK 1393434Updated Nov 11, 2026
OCUL price & chart
Loading TradingView…
NASDAQ:OCUL on TradingView ↗About the company
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
In the news
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 410,882,000Source | 490,369,000Source | 671,317,000Source | 451,333,000Source | 517,091,000Source | 732,529,000Source | 405,920,000Source | 538,947,000Source | 808,057,000Source | 457,935,000Source | 252,060,000Source | 149,289,000Source |
| Property, Plant and Equipment, NetUSD | 16,954,000Source | 10,050,000Source | 19,456,000Source | 10,461,000Source | 10,887,000Source | 18,425,000Source | 10,784,000Source | 11,450,000Source | 19,676,000Source | 9,389,000Source | 11,739,000Source | 9,856,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 344,772,000Source | 427,220,000Source | 598,641,000Source | 391,134,000Source | 459,690,000Source | 666,699,000Source | 349,681,000Source | 482,888,000Source | 737,060,000Source | 392,102,000Source | 195,807,000Source | 102,300,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 30,768,000Source | 30,235,000Source | 30,261,000Source | 30,412,000Source | 30,232,000Source | 24,347,000Source | 25,221,000Source | 26,546,000Source | 30,650,000Source | 32,388,000Source | 26,179,000Source | 21,325,000Source |
| Inventory, NetUSD | 3,488,000Source | 2,405,000Source | 3,826,000Source | 3,039,000Source | 2,547,000Source | 3,737,000Source | 3,269,000Source | 2,574,000Source | 3,564,000Source | 3,040,000Source | 2,305,000Source | 1,974,000Source |
| Assets, CurrentUSD | 386,980,000Source | 473,011,000Source | 644,427,000Source | 433,375,000Source | 498,585,000Source | 705,995,000Source | 387,694,000Source | 519,824,000Source | 782,129,000Source | 440,987,000Source | 232,235,000Source | 129,627,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,952,000Source | 13,151,000Source | 11,699,000Source | 8,790,000Source | 6,116,000Source | 11,212,000Source | 9,523,000Source | 7,666,000Source | 10,855,000Source | 13,457,000Source | 7,794,000Source | 4,028,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,334,000Source | 5,694,000Source | 5,820,000Source | 5,883,000Source | 6,005,000Source | 6,495,000Source | 5,828,000Source | 6,059,000Source | 4,638,000Source | 5,945,000Source | 6,472,000Source | 8,042,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 152,653,000Source | 138,348,000Source | 151,276,000Source | 145,417,000Source | 139,396,000Source | 150,955,000Source | 139,990,000Source | 130,964,000Source | 153,747,000Source | 142,591,000Source | 160,929,000Source | 113,910,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 18,000Source | 16,000Source | 22,000Source | 17,000Source | 16,000Source | 22,000Source | 16,000Source | 15,000Source | 22,000Source | 16,000Source | 12,000Source | 8,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,092,369,000Source | -842,696,000Source | -1,324,398,000Source | -1,022,951,000Source | -806,203,000Source | -1,245,635,000Source | -955,137,000Source | -762,426,000Source | -1,157,023,000Source | -891,084,000Source | -697,578,000Source | -616,842,000Source |
| Stockholders' Equity Attributable to ParentUSD | 258,229,000Source | 352,021,000Source | 520,041,000Source | 305,916,000Source | 377,695,000Source | 581,574,000Source | 265,930,000Source | 407,983,000Source | 654,310,000Source | 315,344,000Source | 91,131,000Source | 35,379,000Source |
| Additional Paid in Capital, Common StockUSD | 1,350,580,000Source | 1,194,701,000Source | 1,844,417,000Source | 1,328,850,000Source | 1,183,882,000Source | 1,827,187,000Source | 1,221,051,000Source | 1,170,394,000Source | 1,811,311,000Source | 1,206,412,000Source | 788,697,000Source | 652,213,000Source |
| Liabilities and EquityUSD | 410,882,000Source | 490,369,000Source | 671,317,000Source | 451,333,000Source | 517,091,000Source | 732,529,000Source | 405,920,000Source | 538,947,000Source | 808,057,000Source | 457,935,000Source | 252,060,000Source | 149,289,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 49,294,000Source | 36,359,000Source | 49,174,000Source | 42,931,000Source | 29,972,000Source | 47,683,000Source | 37,926,000Source | 24,298,000Source | 50,806,000Source | 41,354,000Source | 34,896,000Source | 31,395,000Source |
| Operating Lease, Liability, CurrentUSD | 2,762,000Source | 1,717,000Source | 3,122,000Source | 2,625,000Source | 1,656,000Source | 3,170,000Source | 2,156,000Source | 1,542,000Source | 2,817,000Source | 1,933,000Source | 1,586,000Source | 1,599,000Source |
| Accounts Payable, CurrentUSD | 6,260,000Source | 4,001,000Source | 6,996,000Source | 5,889,000Source | 3,689,000Source | 8,026,000Source | 4,626,000Source | 6,453,000Source | 4,154,000Source | 4,176,000Source | 4,389,000Source | 5,123,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,629,000Source | 5,592,000Source | 3,466,000Source | 4,408,000Source | 6,100,000Source | 4,230,000Source | 4,866,000Source | 6,407,000Source | 2,815,000Source | 5,345,000Source | 6,878,000Source | 8,678,000Source |
| Other Liabilities, NoncurrentUSD | 151,000Source | 117,000Source | 931,000Source | 148,000Source | 114,000Source | 909,000Source | 144,000Source | 111,000Source | 887,000Source | 141,000Source | 108,000Source | 93,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 40,272,000Source | 30,451,000Source | 39,056,000Source | 34,417,000Source | 24,358,000Source | 36,487,000Source | 31,080,000Source | 16,040,000Source | 43,835,000Source | 35,117,000Source | 28,666,000Source | 24,097,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -88,612,000Source | -64,053,000Source | -265,939,000Source | -193,506,000Source | -80,736,000Source | -71,038,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 1,283,000Source | 981,000Source | 4,323,000Source | 3,786,000Source | 2,983,000Source | 2,109,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 15,582,000Source | 10,456,000Source | 43,184,000Source | 33,109,000Source | 17,825,000Source | 16,964,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -6,303,000Source | -7,167,000Source | -1,738,000Source | 6,209,000Source | 4,854,000Source | 190,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 173,000Source | 229,000Source | 524,000Source | 735,000Source | 331,000Source | 724,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,719,000Source | 7,000Source | -887,000Source | -318,000Source | 583,000Source | -621,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -65,993,000Source | -44,671,000Source | -204,883,000Source | -134,677,000Source | -70,234,000Source | -59,603,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -4,662,000Source | -1,933,000Source | -11,880,000Source | -1,288,000Source | -6,087,000Source | -3,715,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 4,662,000Source | 1,933,000Source | 12,010,000Source | 1,288,000Source | 6,087,000Source | 3,715,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 294,000Source | 4,183,000Source | 561,721,000Source | 332,110,000Source | 169,828,000Source | 1,454,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 26,125,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -70,361,000Source | -42,421,000Source | 344,958,000Source | 196,145,000Source | 93,507,000Source | -61,864,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 346,386,000Source | 428,834,000Source | 600,255,000Source | 392,748,000Source | 668,313,000Source | 351,295,000Source | 738,674,000Source | 393,716,000Source | 197,571,000Source | 104,064,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,189,000Source | 2,140,000Source | 9,029,000Source | 21,533,000Source | 5,464,000Source | 2,147,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 11,691,000Source | 6,641,000Source | 14,649,000Source | 9,678,000Source | 15,582,000Source | 10,456,000Source | 43,184,000Source | 33,109,000Source | 17,825,000Source | 16,964,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 1,381,000Source | 1,436,000Source | 3,397,000Source | 3,734,000Source | 6,106,000Source | 4,853,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 13,841,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | 29,000Source | -4,866,000Source | — | 29,000Source | — | -1,000Source | -1,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | -27,950,000Source | 14,190,000Source | — |
| General and Administrative ExpenseUSD | — | — | 16,022,000Source | 12,235,000Source | 22,159,000Source | 14,346,000Source | 20,006,000Source | 16,348,000Source | 64,376,000Source | 60,653,000Source | 33,940,000Source | 32,224,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 3,002,000Source | 3,224,000Source | 2,792,000Source | 3,016,000Source | 2,777,000Source | 2,984,000Source | 11,835,000Source | 13,577,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -69,418,000Source | -36,493,000Source | -78,763,000Source | -67,814,000Source | -88,612,000Source | -64,053,000Source | -265,939,000Source | -193,506,000Source | -80,736,000Source | -71,038,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -80,736,000Source | -71,038,000Source |
| Nonoperating Income (Expense)USD | — | — | -720,000Source | 9,505,000Source | 3,346,000Source | -173,000Source | 4,728,000Source | -136,000Source | 4,078,000Source | -21,725,000Source | 1,646,000Source | 7,616,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | -1,000Source | -1,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 5,184,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 117,261,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 82,474,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 294,000Source | 4,183,000Source | 20,544,000Source | 14,741,000Source | 551,000Source | 514,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 14,544,000Source | 15,425,000Source | 13,475,000Source | 13,459,000Source | 10,785,000Source | 10,698,000Source | 51,951,000Source | 63,723,000Source | 58,443,000Source | 51,494,000Source |
| Cost of RevenueUSD | — | — | 1,774,000Source | 1,561,000Source | 2,011,000Source | 1,944,000Source | 1,329,000Source | 1,262,000Source | 6,574,000Source | 5,626,000Source | 5,281,000Source | 4,540,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -68,698,000Source | -45,998,000Source | -82,109,000Source | -67,641,000Source | -93,340,000Source | -63,917,000Source | -270,017,000Source | -171,781,000Source | -82,382,000Source | -78,654,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | -1,000Source | -1,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -69,418,000Source | -36,493,000Source | -78,763,000Source | -67,814,000Source | -88,612,000Source | -64,053,000Source | -265,939,000Source | -193,506,000Source | -80,736,000Source | -71,038,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.38Source | -0.22Source | -0.35Source | -0.39Source | -0.4Source | -0.38Source | -1.42Source | -1.22Source | -1.01Source | -0.92Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.38Source | -0.22Source | -0.35Source | -0.39Source | -0.4Source | -0.38Source | -1.42Source | -1.22Source | -1.02Source | -0.97Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 183,919,808Source | 166,992,735Source | 224,952,428Source | 172,594,662Source | 224,099,410Source | 169,396,989Source | 187,241,483Source | 158,265,162Source | 79,827,362Source | 76,875,035Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 183,919,808Source | 166,992,735Source | 224,952,428Source | 172,594,662Source | 224,099,410Source | 169,396,989Source | 187,241,483Source | 158,265,162Source | 85,596,594Source | 82,644,267Source |
| Interest Expense (non-operating)USD | — | — | 3,002,000Source | 3,224,000Source | 2,792,000Source | 3,016,000Source | 2,777,000Source | 2,984,000Source | 11,835,000Source | 13,577,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 83,242,000Source | 61,423,000Source | 95,584,000Source | 81,100,000Source | 104,125,000Source | 74,615,000Source | 321,968,000Source | 235,504,000Source | 140,825,000Source | 130,148,000Source |
| General and Administrative ExpenseUSD | — | — | 16,022,000Source | 12,235,000Source | 22,159,000Source | 14,346,000Source | 20,006,000Source | 16,348,000Source | 64,376,000Source | 60,653,000Source | 33,940,000Source | 32,224,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 11,338,000Source | 7,022,000Source |
| Investment Income, NetUSD | — | — | 3,729,000Source | 5,653,000Source | 5,449,000Source | 3,455,000Source | 6,050,000Source | 3,826,000Source | 18,355,000Source | 20,282,000Source | 3,983,000Source | 798,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -80,736,000Source | -71,038,000Source |
| Nonoperating Income (Expense)USD | — | — | -720,000Source | 9,505,000Source | 3,346,000Source | -173,000Source | 4,728,000Source | -136,000Source | 4,078,000Source | -21,725,000Source | 1,646,000Source | 7,616,000Source |
| Research and Development ExpenseUSD | — | — | 52,358,000Source | 37,054,000Source | 54,138,000Source | 51,081,000Source | 66,213,000Source | 42,857,000Source | 197,096,000Source | 127,635,000Source | 61,055,000Source | 53,462,000Source |
| Selling and Marketing ExpenseUSD | — | — | 13,088,000Source | 10,573,000Source | 17,276,000Source | 13,729,000Source | 16,577,000Source | 14,148,000Source | 53,922,000Source | 41,590,000Source | 40,549,000Source | 39,922,000Source |
Filing attachments
tm2629079d2_ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on submission package under 505(b)(2) pathway SOL-1 post-hoc analyses presented at AAO and Empire Forum show subjects without early persistent retinal fluid and fluid variability ha…
Read attachment ↗tm2621618d1_ex99-1.htm · 8-K · 2026-08-03
EX-99.1 2 tm2621618d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights Ocular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient to Support Submission of AXPAXLI NDA in wet AMD AXPAXLI NDA submission to be based on SOL-1 Week 52 efficacy and safety data, …
Read attachment ↗tm2613442d1_ex99-1.htm · 8-K · 2026-05-05
EX-99.1 2 tm2613442d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula…
Read attachment ↗ocul-20251231xex4d4.htm · 10-K · 2026-02-05
Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Ocular Therapeutix, Inc. is intended as a summary only and therefore is not a complete description. The following description is qualified by reference to our certificate of incorporation, which we refer to as our “Certificate of Incorporation”; our by-laws, which we refer to as our “By-laws”; and applicable provisions of the Delaware General Corporation …
Read attachment ↗tm265061d1_ex99-1.htm · 8-K · 2026-02-05
Exhibit 99.1 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on SOL-1 52 Week data, pending positive results and planned FDA interactions Completed randomization of 631 subjects in SOL-R Phase 3 non-inferiority trial in December 2025; timing …
Read attachment ↗tm2530039d1_ex99-1.htm · 8-K · 2025-11-04
EX-99.1 2 tm2530039d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization of 555 subjects Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on tr…
Read attachment ↗